These two authors contributed equally to this paper.
Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy
Article first published online: 21 MAR 2012
© 2012 The Authors. Journal of Digestive Diseases © 2012 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and Blackwell Publishing Asia Pty Ltd.
Journal of Digestive Diseases
Volume 13, Issue 4, pages 219–224, April 2012
How to Cite
HAN, X. F., WANG, Q. X., LIU, Y., YOU, Z. R., BIAN, Z. L., QIU, D. K. and MA, X. (2012), Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy. Journal of Digestive Diseases, 13: 219–224. doi: 10.1111/j.1751-2980.2012.00574.x
- Issue published online: 21 MAR 2012
- Article first published online: 21 MAR 2012
- Accepted manuscript online: 9 JAN 2012 01:00PM EST
- alkaline phosphatase;
- combination therapy;
- primary biliary cirrhosis;
- ursodeoxycholic acid
OBJECTIVE: To investigate the efficacy of fenofibrate combination therapy in Chinese patients with primary biliary cirrhosis (PBC) who had a partial response to standard dose of ursodeoxycholic acid (UDCA) for at least one year.
METHODS: PBC patients were treated with UDCA (13–15 mg/kg/day) for more than one year. The biochemical response to UDCA treatment was evaluated after treatment. Fenofibrate (200 mg/day) was added to 22 patients with partial response to UDCA.
RESULTS: In patients with partial response to UDCA, serum alkaline phosphatase (ALP) and γ-glutamyl transpeptidase levels significantly decreased after 3-month combination therapy of UDCA and fenofibrate, 68% of these patients even reached normal ALP level. Serum triglyceride (TG) and cholesterol levels were improved, and alanine transaminase (ALT) and aspartate transaminase (AST) were also decreased during the combination therapy. However, fenofibrate had no significant effect on serum bilirubin levels. The improvement of liver biochemical tests was maintained in some patients with long-term therapy (at least 6 months). No obvious adverse effects were observed in patients taking fenofibrate.
CONCLUSIONS: Fenofibrate is effective for improving liver biochemical tests in patients who have partial response to UDCA monotherapy. It is worth exploring the efficacy of fenofibrate on histological changes in PBC patients.